Top

02-08-2018 | Insulin | Article

Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials

Journal: Acta Diabetologica

Authors: Xiao-Wen Zhang, Xin-Lin Zhang, Biao Xu, Li-Na Kang

Publisher: Springer Milan

Abstract

Aims

To determine the safety and efficacy of insulin degludec versus glargine in patients with type 1 (T1D) and type 2 (T2D) diabetes mellitus.

Methods

Databases were searched until July 5, 2017. We included randomized controlled trials comparing degludec with glargine in diabetic patients, each with a minimum of 16 weeks of follow-up.

Results

Eighteen trials with 16,791 patients were included. Degludec was associated with a statistically significant reduction in risk for all confirmed hypoglycemia at the maintenance treatment period [estimated rate ratio (ERR) 0.81; 95% confidence interval (CI) 0.72‒0.92; P = 0.001], nocturnal confirmed hypoglycemia at the entire (ERR 0.71; 95% CI 0.63‒0.80; P < 0.001) and maintenance treatment period (ERR 0.65; 95% CI 0.59‒0.71; P < 0.001), all irrespective of the pooled diabetic populations and follow-up durations. The differences in the rate of hypoglycemia were more pronounced in nocturnal period and maintenance period and in T2D than T1D patients. Degludec reduced the incidence of severe hypoglycemia in T2D [ERR 0.65; (0.52; 0.89); P = 0.005] but not T1D patients. HbA1c concentration was slightly higher in degludec over glargine but was not clinically relevant [estimated treatment difference (ETD) 0.03; 95% CI − 0.00 to 0.06%; P = 0.06]. Fasting plasma glucose level was lower in degludec-treated patients (ETD − 0.28 mmol/L; 95% CI − 0.44 to − 0.11 mmol/L; P = 0.001). Several subgroup analyses showed largely consistent findings. The rates of adverse events including total mortality and cardiovascular events were not significantly different between two treatment strategies.

Conclusions

Insulin degludec appears to have better safety in reducing hypoglycemic events with similar efficacy compared with insulin glargine.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed

Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653CrossRefPubMed

Curtis B, Lage MJ (2014) Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 17:21–31CrossRefPubMed

Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C et al (2004) Lower within-subject variability of insulin detemirin comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620CrossRefPubMed

Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD (2008) Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabet Care 31:1112–1117CrossRef

Pettus J, Santos CT, Tamborlane WV, Edelman S (2016) The past, present, and future of basal insulins. Diabetes Metab Res Rev 32:478–496CrossRefPubMed

Vora J, Cariou B, Evans M, Gross JL, Harris S, Landstedt-Hallin L et al (2015) Clinical use of insulin degludec. Diabet Res Clin Pract 109:19–31CrossRef

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H (2012) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabet Obes Metab 14:859–864CrossRef

Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H (2012) Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabet Obes Metab 14:944–950CrossRef

10.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379:1489–1497CrossRefPubMed

11.

Garber AJ, King AB, Del PS, Sreenan S, Balci MK, Munoz-Torres M et al (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379:1498–1507CrossRefPubMed

12.

Ratner RE, Gough SC, Mathieu C, Del PS, Bode B, Mersebach H et al (2013) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabet Obes Metab 15:175–184CrossRef

13.

Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC (2013) Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging 30:1009–1018CrossRefPubMedPubMedCentral

14.

Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347:f4533CrossRefPubMed

15.

McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA (2012) Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 35:1897–1901CrossRefPubMedPubMedCentral

16.

Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418CrossRefPubMed

17.

Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 318:33–44CrossRefPubMedPubMedCentral

18.

Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 318:45–56CrossRefPubMedPubMedCentral

19.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723CrossRefPubMedPubMedCentral

20.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–269):W64

21.

Higgins JPT, Altman DG, Sterne JAC (2011) Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane.org/resources/handbook. 15 Dec 2015

22.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentral

23.

Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A et al (2013) Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabet Endocrinol 1:123–131CrossRef

24.

Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A et al (2011) A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabet Care 34:669–674CrossRef

25.

Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T et al (2012) Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabet Care 35:2464–2471CrossRef

26.

Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM (2013) Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabet Care 36:2536–2542CrossRef

27.

Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S (2013) Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabet Investig 4:605–612CrossRef

28.

Onishi Y, Ono Y, Rabol R, Endahl L, Nakamura S (2013) Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabet Obes Metab 15:826–832CrossRef

29.

Kumar A, Franek E, Wise J, Niemeyer M, Mersebach H, Simo R (2016) Efficacy and safety of once-daily insulin degludec/insulin aspart versus insulin glargine (U100) for 52 weeks in insulin-naive patients with type 2 diabetes: a randomized controlled trial. PLoS ONE 11:e163350

30.

Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT et al (2016) A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naive patients with type 2 diabetes mellitus. Drugs R D 16:239–249CrossRefPubMedPubMedCentral

31.

Kumar S, Jang HC, Demirag NG, Skjoth TV, Endahl L, Bode B (2017) Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study. Diabet Med 34:180–188CrossRefPubMed

32.

Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M et al (2013) The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabet Care 36:858–864CrossRef

33.

Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D et al (2013) Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 98:1154–1162CrossRefPubMedPubMedCentral

34.

Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA et al (2011) Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabet Care 34:661–665CrossRef

35.

Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B (2016) A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med 33:478–487CrossRefPubMed

36.

Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del PS (2015) Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 25:898–905CrossRefPubMed

37.

Monami M, Mannucci E (2013) Efficacy and safety of degludec insulin: a meta-analysis of randomised trials. Curr Med Res Opin 29:339–342CrossRefPubMed

38.

Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397CrossRefPubMedPubMedCentral

39.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J et al (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007:D5613

40.

Lingvay I, Perez MF, Garcia-Hernandez P, Norwood P, Lehmann L, Tarp-Johansen MJ et al (2016) Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315:898–907CrossRefPubMed

41.

Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE et al (2018) Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia 61:48–57CrossRefPubMed

42.

Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS et al (2018) DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 61:58–65CrossRefPubMed

43.

Seaquist ER, Chow LS (2017) Hypoglycemia in diabetes: does insulin type matter? JAMA 318:31–32CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »